When destiny doesn't pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan.

Schulte, Brian C; Hwang, Caleb; Horvai, Andrew E; Olivier, Timothee

Schulte, Brian C; Hwang, Caleb; Horvai, Andrew E; Olivier, Timothee.

Afiliação

Schulte BC; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Hwang C; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Horvai AE; School of Medicine, University of California San Francisco, San Francisco, California, USA.
Olivier T; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.

Cancer ; 2024 Aug 25.

Article em En | MEDLINE | ID: mdl-39182174

Palavras-chave

HER2targeted therapy; US Food and Drug Administration (FDA) approval; sarcoma; trastuzumab deruxtecan (TDXd)

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google